HHS Secretary Robert F. Kennedy Jr. and CMS head Dr. Mehmet Oz are withholding $867.5 million from California, citing a crackdown on home-care fraud.
The Department of Health and Human Services (HHS) has moved to freeze $867.5 million in federal Medicaid payments to California, signaling a sharp escalation in the federal government’s scrutiny of state-run healthcare programs. HHS Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, who leads the Centers for Medicare & Medicaid Services (CMS), characterized the deferral as a necessary step to protect taxpayer dollars from waste and fraud. This action is part of a broader “war on fraud” that has also seen $199 million deferred from Minnesota, totaling an unprecedented $3 billion campaign against Democratic-led states in 2026.
The freeze specifically targets California’s home- and community-based services, a sector that has seen spending grow by 24 percent over the last two years—double the national average. Federal regulators identified 14 high-risk service areas, including $221 million in claims linked to beneficiaries with unsatisfactory immigration status and various payments made for services billed after a patient’s death. Dr. Oz defended the aggressive posture, stating that if a claim appears fraudulent, the federal government will no longer provide immediate reimbursement. This shift to “stop the fraud before it happens” represents a significant departure from previous pay-and-chase models of federal oversight.
This fiscal tightening arrives as California and Minnesota face a combined withholding of more than $3 billion in Medicaid funds throughout 2026. While the administration frames these actions as temporary pauses pending better documentation, health policy analysts warn that the move could destabilize the infrastructure for in-home care. For many elderly and disabled residents, these programs are the only alternative to more expensive institutional nursing home care. Critics argue the move punishes states that have prioritized home-based independence over traditional hospital settings, potentially leaving millions of beneficiaries and safety-net providers at risk if the pause converts to permanent disallowances.
Simultaneously, the nation’s public health apparatus is facing a mounting crisis on a different front. The Centers for Disease Control and Prevention (CDC) reports that measles cases have reached 2,318 this year, the highest burden in 35 years. Former public health officials have expressed alarm over the surge, noting that the CDC has lacked a permanent director for much of the current term. They point to a January 2026 revision of the childhood vaccine schedule, ordered by the administration despite a lack of new clinical data, as a factor in declining vaccination coverage. Experts have labeled the surge a “profound moral failure,” noting that cases in the last 18 months have exceeded the previous 25 years combined.
While federal leadership focuses on fiscal integrity and rooting out Medicaid fraud, the “canary in the coal mine” of the measles outbreak suggests a broader unraveling of public health capacity. The administration has overseen significant staffing and funding cuts to prevention programs, shifting the focus toward individual responsibility and market-based health solutions. This occurs as the country confronts a simultaneous rise in other threats, including bird flu, whooping cough, and cyclosporiasis, the latter of which recently saw 2,500 new cases reported across four additional states.
In other health developments, the FDA recently authorized a new coronary inflammation biomarker, CaRi-Heart, which aims to identify cardiovascular mortality risk up to a decade in advance. Additionally, the National Organization for Rare Disorders expanded its network of Excellence Centers to include new institutions in California, New York, and North Carolina. Private philanthropy also continues to fill gaps, with the Harry T. Mangurian, Jr. Foundation committing an additional $4 million to blood cancer research. These private-sector innovations highlight the continued push for medical advancement even as the federal government tightens the purse strings on state-administered programs.

